MAP2K7 and melanoma: A phase III trial with patients with BRAF-mutated melanoma showed a significant prolongation of overall survival if treated with Trametinib, a Mitogen-activated protein kinase kinase (MEK) inhibitor, together with Dabrafenib, a BRAF inhibitor [59].